The Joint Corp. (JYNT) Market Cap
The Joint Corp. has a market capitalization of $123.7M.
Financials based on reported quarter end 2025-12-31
Price: $8.64
▲ 0.06 (0.70%)
Market Cap: 123.75M
NASDAQ · time unavailable
CEO: Sanjiv Razdan
Sector: Healthcare
Industry: Medical - Care Facilities
IPO Date: 2014-11-11
Website: https://www.thejoint.com
The Joint Corp. (JYNT) - Company Information
Market Cap: 123.75M · Sector: Healthcare
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
Analyst Sentiment
Based on 8 ratings
Analyst 1Y Forecast: $0.00
Average target (based on 1 sources)
Consensus Price Target
Low
$20
Median
$20
High
$20
Average
$20
Potential Upside: 131.5%
Price & Moving Averages
Related Companies in Healthcare
JOURNEY MEDICAL CORP (DERM)
Healthcare
$0.12B
Mkt Cap
TREACE MEDICAL CONCEPTS INC (TMCI)
Healthcare
$0.12B
Mkt Cap
AARDVARK THERAPEUTICS INC (AARD)
Healthcare
$0.12B
Mkt Cap
OPTIMIZERX CORP (OPRX)
Healthcare
$0.13B
Mkt Cap
INHIBIKASE THERAPEUTICS INC (IKT)
Healthcare
$0.13B
Mkt Cap
CARDIFF ONCOLOGY INC (CRDF)
Healthcare
$0.12B
Mkt Cap
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"The Joint Corp. (JYNT) reported a revenue of $15.17M and a net income of $991.1k for the year ending December 31, 2025. The company demonstrates a profitable operation with earnings per share (EPS) of $0.07. Despite its profitability, the market performance reflects challenges, with a 1-year price change of -34.43%, suggesting a significant drop in investor sentiment. The company maintains a solid financial position with total assets of $60.97M against total liabilities of $45.89M, resulting in total equity of $15.08M and negative net debt of -$21.59M, indicating a strong liquidity position. Operating cash flow is positive at $2.9M, which supports the company's operational effectiveness. However, with no dividends paid, the focus remains on growth rather than immediate shareholder returns. Analysts have a target price consensus of $20, signaling potential upside but with caution due to the current share price of $8.38. Overall, while JYNT is profitable, the declining stock performance may raise concerns about its growth trajectory."
Revenue Growth
Revenue is positive but minimal compared to larger industry players.
Profitability
Net income is positive, reflecting effective cost management.
Cash Flow Quality
Strong operating cash flow indicates solid operational performance.
Leverage & Balance Sheet
Healthy balance sheet with negative net debt showcases financial stability.
Shareholder Returns
No dividends and significant stock price depreciation impact returns.
Analyst Sentiment & Valuation
Target price suggests value, but risks remain given recent stock performance.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
So what? Management is leaning on a near-term pathway: complete Joint 2.0 by end of 2025 and finish refranchising mid-2026 to unlock a step-up in margins (run-rate adjusted EBITDA margin 19%-21% vs 12% in 2025; G&A 40%-42% vs 64%). However, Q&A pressure centered on the real near-term limiter: comps are down (Q4 system-wide -3.9%, comp -3.8%) because new patient count is weak—Scott repeatedly framed the issue as 'fewer new customers coming in,' not attrition or conversion collapsing. While early SEO/AI search lead indicators and retention pilots (AlignOne/AlignTwo) sound constructive, executives admitted it takes time for marketing/SEO to show through on comps and that comps in Q1-Jan/Feb have been 'similar trends' to Q4. Guidance (-3% to +3% comp) notably excludes pricing, despite a $2/$5/$10 pilot in ~300 clinics. In short: the long-term pure-play story is clear; the market-facing KPI inflection still depends on lead generation timing.
Growth Catalysts
- Joint 2.0 transformation on track to complete by end of 2025 (pure-play franchisor model starting mid-2026)
- Marketing message pivot from broad wellness to chiropractic pain relief (aimed at higher-yield patient demand)
- National-scale marketing + SEO improvements targeting AI-driven search behavior (microsites migrated to new template; SEO traction moving toward/above benchmark)
- Conversion focus in-clinic (new operations leader Ron Stilwell joined Jan 2026; wellness coordinators trained on lead conversion scripts)
- Retention/attrition mitigation via low-frequency plans: AlignOne ($35/month, 1 adjustment minimum) and test of AlignTwo (2 visits/month)
Business Development
- Signed asset purchase agreement to sell 22 corporate-owned/managed clinics for $1.5M to three buying groups (lease reassignments expected completed in Q2)
- Entered letter of intent in March for sale of five additional corporate-owned/managed clinics
- All but two of remaining 48 company-owned clinics are in California
Financial Highlights
- Q4 revenue (continuing ops) +3.1% YoY to $15.2M
- Q4 consolidated adjusted EBITDA +7.8% YoY to $3.6M; continuing operations adjusted EBITDA $1.6M vs $2.0M last year
- Q4 consolidated net income $1.0M
- Q4 system-wide sales -3.9% to $140.0M; comp sales -3.8%
- Full year system-wide sales $532M flat; comp sales -0.4%; consolidated adjusted EBITDA +13.9% to $13.0M
- Full year revenue $54.9M vs $52.2M in 2024; consolidated net income improved by $8.7M to $2.9M (vs $5.8M loss in 2024)
- 2026 pure-play run-rate targets: gross margin 83%-85% of revenue (vs 90% in 2025); G&A 40%-42% of revenue (vs 64% in 2025); adjusted EBITDA margin 19%-21% (vs 12% in 2025); net income margin 13%-15% (vs 3% in 2025)
- No pricing increase included in 2026 guidance (pricing pilot in test at time of guidance)
Capital Funding
- Q4 repurchase: 1,100,000 shares for $9.0M (avg $8.45/share)
- Full-year repurchase: 1,300,000 shares for $11.3M (avg $8.73/share)
- Unrestricted cash at 12/31/2025: $23.6M (vs $25.1M prior year end)
- Revolver (JPMorgan Chase): $20.0M capacity; zero drawn during the quarter
- Remaining authorization for share repurchases: $5.7M as of end of 2025
Strategy & Ops
- Refranchising progress: corporate-owned clinics reduced from 135 at start of process to 48 remaining (5% of portfolio) after signing sale of 22 clinics and LOI for 5 more
- Clinic sales/QC improvement: preopening protocol resulted in clinics reaching breakeven in half the time vs prior years
- Marketing funnel shift: more top-of-funnel national spend starting Nov 2025; additional digital/SEO work including AI-search visibility
- Technology/product feedback: >23,000 patient app surveys, avg rating 4.91/5; 75% waited <5 minutes; intent to recommend 9.7/10
- Pricing pilot: three-tier increases ($2/$5/$10); $2 increase showed little effect; focus on $5 and $10; rollout tested in ~300 clinics
Market Outlook
- 2026 guidance initiated: system-wide sales $540M-$552M; comp sales -3% to +3%; consolidated adjusted EBITDA $12.5M-$13.5M
- Comp inflection expectation: management indicated 2H should be 'quite a bit better' driven by easier compares in back half and traction from marketing/SEO + operational initiatives
- Guidance assumption explicitly excludes additional enterprise-wide pricing increase (pilot results not yet known at time of guide)
Risks & Headwinds
- Primary pressure on comps: 'fewer new customers coming in' (new patient flow described as weakest component of active member growth; conversion/attrition slightly better YoY)
- Q4 comps were lower than expected 'largely due to lower new patient count'
- AI-driven search behavior shift is a 'moving target' requiring ongoing investment and time to translate into comp inflection
- Macro sensitivity by customer income: management noted ~70% of patients in household income $60k-$110k and said they have felt macro impact more than some others (relevant to pricing/affordability testing)
- Transition costs/temporary headwinds: selling & marketing up 25% in Q4 due to enhanced national marketing and 'one-off costs' for moving to a new marketing agency; G&A still rising 2% as payroll increases associated with refranchising transition
- Geographic performance variability: California clinics described as 'better performers' vs Southeast clinics; potential productivity dispersion across portfolio
Sentiment: CAUTIOUS
Note: This summary was synthesized by AI from the JYNT Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.